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Abstract
In recent years, we have successfully established a novel method of haploidentical haematopoietic stem cell transplantation (HSCT)
without in vitro T-cell depletion. This study was aimed at analysing the incidence and risk factors of invasive fungal infection (IFI) with
this transplantation method. The study comprised 291 patients who had undergone haploidentical HSCT from 1 January 2007 to 31
December 2008. IFI was diagnosed according to the European Organization for Research and Treatment of Cancer/Mycoses Study
Group 2002 criteria, and only proven or probable cases of IFI were regarded as true cases. A total of 39 patients were documented as
having IFI, including four proven cases and 35 probable cases. The median time of diagnosis was 26 days (range: 6–405 days) after trans-
plantation. The cumulative incidence rates of IFI at 40 days, 1 year, 2 years and 3 years after transplantation were 8.25%, 13.1%, 13.4%
and 13.4%, respectively. Multivariate analysis identiﬁed platelet engraftment time (>17 days) (p 0.027; hazard ratio (HR) 2.432;
95% CI 1.105–5.355), a high risk of underlying disease (p 0.001; HR 2.916; 95% CI 1.515–5.611) and grade III–IV acute graft-versus-host
disease (p 0.019; HR 2.407; 95% CI 1.154–5.022) as risk factors for IFI. The incidence rates of IFI in patients with no, one, two or three
risk factors at 3 years after transplantation were 4.48%, 7.86%, 29.6% and 23.1%, respectively. In conclusion, IFI is an important compli-
cation following haploidentical HSCT without in vitro T-cell depletion.
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Introduction
Haploidentical haematopoietic stem cell transplantation
(HSCT) is an effective option for patients with haematological
malignancies without human leukocyte antigen (HLA)-matched
siblings or unrelated donors. Long-lasting immunosuppression
and severe graft-versus-host disease (GVHD), however, lead
to high incidence rates of opportunistic infections. Invasive
fungal infection (IFI) has been one of the major infectious
complications after allogeneic HSCT, with a mortality rate of
up to 80% [1]. The incidence of IFI varies in different
transplantation models, and data for IFI from haploidentical
HSCT cases are scarce.
Recently, we developed a new method for haploidentical
allogeneic HSCT from family donors without in vitro T-cell
depletion (TCD) [2–4]. Long-term outcomes were compara-
ble to that of transplantation with HLA-matched siblings or
unrelated persons as donors. Opportunistic infections, how-
ever, can occur in up to 39% of patients [4]. The incidence and
risk factors related to IFI in the haploidentical HSCT model
have not been studied. Our study analysed the incidence and
risk factors related to IFI for this transplantation model.
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Patients and Methods
Patients
Patients without HLA-matched siblings or unrelated donors
were potential candidates for allogeneic HSCT from haplo-
identical family donors. From 1 January 2007 to 31 Decem-
ber 2008, 291 patients underwent haploidentical HSCT
without in vitro TCD at the Peking University Institute of
Haematology. All patients signed informed consent forms
prior to treatment, and the treatment programme was
approved by the Ethics Committee of Peking University Peo-
ple’s Hospital. The characteristics of all HSCT recipients are
summarized in Table 1.
Transplantation procedure
The transplantation procedure has been described in previ-
ous reports [2–4]. The modiﬁed busulphan/cyclophospha-
mide + antithymocyte globulin conditioning regimen was
used to treat 288 patients. The regimen was as follows: cyto-
sine arabinoside (4 g/m2/day, days –10 to –9), busulfan
(0.8 mg/kg, every 6 h, 12 doses, days –8 to –6), cyclophos-
phamide (1.8 g/m2/day, days –5 to –4), simustine (Me-CCNU,
250 mg/m2, day –3), and thymoglobulin (rabbit antithymocyte
globulin (Sangstat-Genzyme, Marcy L’Etoile, France), 2.5 mg/
kg, days –5 to –2). The other three patients were treated
with ﬂudarabine (30 mg/m2, days –6 to –2) instead of cyclo-
phosphamide. The patients received cyclosporin A, myco-
phenolate mofetil and short-term methotrexate for GVHD
prophylaxis. Chimerism was determined with at least two of
the following three methods: DNA-based HLA typing (for
mismatched loci), PCR-based DNA ﬁngerprinting of short
tandem repeats, and chromosomal ﬂuorescence in situ
hybridization (for the Y chromosome). At 30, 60, 90, 180
and 365 days after transplantation, chimerism and peripheral
blood lymphocytes (absolute lymphocyte numbers, CD4+
cells) were determined.
IFI prophylaxis
A total of 23 patients had a prior history of IFI: two patients
were proven cases, six patients were probable cases, and 15
patients were possible cases. For prophylaxis during the
transplantation period, three patients were treated with oral
ﬂuconazole, four were treated with amphotericin B, three
were treated with voriconazole, two were treated with
caspofungin, and 11 were treated with intravenous itraconaz-
ole. Of the 268 patients without a previous history of IFI,
eight were treated with an itraconazole oral solution, three
were treated with micafungin, and the remaining 257 were
treated with oral ﬂuconazole (200 mg/day). The prophylaxis
lasted until 75 days after transplantation or until empirical/
pre-emptive antifungal treatment was given.
Diagnosis of IFI
According to the European Organization for Research and
Treatment of Cancer (EORTC)/Mycoses Study Group criteria
[5], IFI can be categorized as proven, probable or possible
cases. In our study, only proven and probable cases were
regarded as true cases. For proven cases, the diagnosis time
was deﬁned as the time at which histopathological evidence
or the results of a sterile tissue culture were acquired. The
diagnosis time for probable cases was the time at which posi-
tive results for culture/galactomannan (GM) were acquired. A
GM index of ‡0.5 for two consecutive instances was regarded
as positive. IFI was divided into early IFI (£40 days) or late IFI
(>40 days) according to the time of occurrence.
Deﬁnitions
Successful neutrophil engraftment was deﬁned as ‡0.5 · 109/
L for three consecutive days, and successful platelet engraft-
ment was deﬁned as ‡20 · 109/L for seven consecutive days
without the need for transfusion. The patients were deﬁned
as high risk if they were in more than the third complete
remission of acute leukaemia; were not in remission; had
chronic myelogenous leukaemia beyond the ﬁrst chronic
TABLE 1. Characteristics of all haematopoietic stem cell
transplant recipients (N = 291)
Variables Value
Age (years), median (range) 25 (5–57)
Recipient sex, n (%)
Male 176 (60.5)
Female 115 (39.5)
Underlying diseases, n
AL 217
CML 44
MM 2
MDS 19
SAA 8
NHL 1
Risk, n (%)
Standard risk 234 (80.4)
High risk 57 (19.6)
Number of mismatched HLA loci, n (%)
3 178 (61.2)
2 87 (29.9)
1 26 (8.9)
Donor/recipient blood type, n
Matched 155
Major mismatched 50
Minor mismatched 67
Bidirectional mismatched 19
Donor/recipient sex
F–M/F–F/M–M/M–F, n 88/58/89/56
Previous IFI history, n (%) 23 (7.9)
IFI prophylaxis, n (%)
Fluconazole 260 (89.3)
Other 31 (10.7)
AL, acute leukaemia; CML, chronic myelogenous leukaemia; F, female; HLA,
human leukocyte antigen; M, male; MDS, myelodysplastic syndrome; MM, multi-
ple myeloma; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anaemia.
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phase. The other cases were deﬁned as standard risk. The
diagnosis and classiﬁcation of GVHD was conducted accord-
ing to the previous consensus [6,7]. IFI was regarded as the
primary cause of death when the patient died of progressive
organ failure, in which IFI was ﬁrst found in the absence of
other comorbidities, excluding GVHD.
Statistical analysis
The following variables were recorded and analysed: gender,
age, type of underlying disease, underlying disease status,
number of mismatched HLA loci (A/B/DRB1), neutrophil
engraftment time, platelet engraftment time, previous history
of IFI, antifungal prophylaxis, acute GVHD, chronic GVHD,
reactivation of cytomegalovirus, and relapse of underlying
disease. Statistical analyses were performed with SPSS 13.0
software. Grouped variables were compared by use of the
chi-squared test, and continuous variables were compared by
use of the non-parametric Mann–Whitney test. Risk factors
were analysed with a Cox proportional hazard model. Acute
GVHD and chronic GVHD were regarded as time-depen-
dent variables. The Kaplan–Meier curve was used to present
survival curves, and the cumulative incidence was analysed
for competing risk with R software. A p-value of <0.05 for
the two-sided test was considered to be statistically signiﬁ-
cant. The patients were followed until 30 March 2011, with
a median follow-up time of 882 days (range: 9–1486 days).
Results
Clinical results
There were 291 patients enrolled in this study. Full donor
chimerism was achieved in all patients. The median time for
successful neutrophil engraftment was 13 days (range: 9–
29 days). Successful platelet engraftment occurred in 262
cases, and the median time for successful platelet engraft-
ment was 17 days (range: 7–180 days). The cumulative inci-
dence rates for acute GVHD of grades II–IV or III–IV at
100 days after transplantation were 47% and 14.7%, respec-
tively. The 255 patients who survived for more than
100 days were evaluated for chronic GVHD, and the cumula-
tive incidence rates of limited and extensive chronic GVHD
at 3 years were 33.3% and 23.1%, respectively. The cumula-
tive relapse rate at 3 years was 16.2%. The overall survival
rate at 3 years was 64.6%, and the survival rate of the stan-
dard-risk group was signiﬁcantly higher than that of the high-
risk group (68.4% vs. 49.1%, respectively, p 0.002).
Peripheral blood lymphocytes were detected at ﬁxed
time-points (Fig. 1). Although the CD4+ cell count gradually
recovered, the absolute CD4+ cell number was <400/lL at
1 year after transplantation.
The incidence and clinical features of IFI
A total of 39 patients were documented as having IFI, includ-
ing four proven cases and 35 probable cases (Table 2). The
median time of IFI occurrence was 26 days (range: 6–
405 days) after transplantation. The most common infection
site was the lung, and 31 cases (79.5%) involved only the
lungs. The other eight patients had disseminated infections.
In one case, the infection occurred in the lumbar spine. Five
cases involved the lungs and the central nervous system
simultaneously or successively. In one case, the infection dis-
seminated to the lungs, spleen, and the soft tissue of the
foot. Most cases lacked direct microbiological evidence.
Three proven cases were infected with Aspergillus plus Bacil-
lus licheniformis, Mucor plus Rhizopus and Candida krusei, and
Aspergillus fumigatus, respectively. The other proven case was
diagnosed according to the septate hyphae in the lung biopsy
specimen, but the speciﬁc strain could not be identiﬁed. Of
the 35 probable cases, only three had direct evidence of
Aspergillus, and the others were diagnosed according to the
GM test. The cumulative incidence rates of IFI at 40 days,
1 year, 2 years and 3 years after transplantation were 8.25%,
13.1%, 13.4% and 13.4%, respectively.
Risk factors for IFI
Table 3 shows the results of the univariate and multivariate
analyses. The univariate analysis demonstrated that a high
risk of underlying disease (p 0.004), neutrophil engraftment
FIG. 1. The reconstitution of peripheral blood lymphocytes after ha-
ploidentical haematopoietic stem cell transplantation. (a) Absolute
lymphocyte counts. (b) CD4+ cell numbers.
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TABLE 2. Invasive fungal infection after haploidentical haematopoietic stem cell transplantation
ID
Prior
IFI Prophylaxis
Time of
IFI (days) Imaging Pathogen GM Diagnosis
Site of
infection Treatment Outcome
Cause
of death
4058594 No Fluconazole 10 Dense lesion – + P L Caspofungin Death IFI
4061011 No Fluconazole 159 Cavity – + P L Micafungin Death DAH
4061385 No Fluconazole 163 NS – + P L Voriconazole Alive –
4061520 No Fluconazole 155 NS – + P L Itraconazole Alive –
4055517 No Fluconazole 102 CNS lesion – + P L + CNS Voriconazole Death IFI
4063238 No Fluconazole 28 NS – + P L Micafungin Alive –
4058305 No Fluconazole 222 NS – + P L Itraconazole Death Relapse
4059365 No Fluconazole 14 Cavity Aspergillus + P L + CNS Itraconazole Death IFI
4062852 No Fluconazole 53 NS – + P L Itraconazole Alive –
4065860 No Fluconazole 214 – Aspergillus ND C Lumbar Amphotericin B Alive –
4046090 No Fluconazole 27 NS – + P L Itraconazole Death IFI
4066238 Yes Fluconazole 31 NS – + P L Itraconazole Alive –
4066318 No Itraconazole 24 NS – + P L Itraconazole Death Other
4061465 No Fluconazole 11 NS – + P L Itraconazole Alive –
4068175 No Fluconazole 29 Cavity – + P L Itraconazole Death IFI
4070559 No Fluconazole 26 Cavity – + P L + CNS Voriconazole Death IFI
4071631 No Fluconazole 21 Cavity – + P L Itraconazole Death IFI
4071827 No Fluconazole 18 Air crescent – + P L Itraconazole Death IFI
4072144 Yes Amphotericin B 6 Cavity Aspergillus fumigatus + C L Voriconazole Death IFI
292590 No Fluconazole 8 Nodule – + P L Voriconazole Death Relapse
4077848 No Fluconazole 13 NS Aspergillus + P L + CNS Itraconazole Death IFI
4072652 No Fluconazole 22 Disseminated Mixed + C D Amphotericin B Death Other
4078950 Yes Caspofungin 20 NS – + P L Caspofungin Death Relapse
4077751 No Fluconazole 26 NS – + P L Itraconazole Death IFI
4066683 No Fluconazole 21 Air crescent – + P L Amphotericin B Death Relapse
4081004 No Fluconazole 230 NS – + P L Caspofungin Death IFI
4077669 No Fluconazole 324 NS – + P L Itraconazole Death Relapse
4082237 Yes Voriconazole 337 NS – + P L Itraconazole Death Relapse
4082592 No Fluconazole 316 NS – + P L Itraconazole Death Relapse
4083345 No Fluconazole 405 NS Aspergillus + P L + CNS Amphotericin B Death IFI
4085026 No Fluconazole 14 NS – + P L Itraconazole Death Other
4083419 No Fluconazole 12 NS – + P L Itraconazole Death IFI
4086708 No Fluconazole 23 Cavity – + P L Itraconazole Death IFI
4078419 No Fluconazole 9 Cavity – + P L Itraconazole Alive –
4088390 No Fluconazole 7 Cavity – + P L Itraconazole Death IFI
4090075 No Fluconazole 10 NS – + P L Itraconazole Alive –
4091170 No Fluconazole 14 Cavity – + P L Itraconazole Death Other
4091855 No Fluconazole 16 Air crescent Aspergillus + C L Itraconazole Alive –
C, proven; CNS, central nervous system; D, disseminated; DAH, diffuse alveolar hemorrhage; GM, galactomannan; IFI, invasive fungal infection; L, lung; ND, not detected; NS,
non-speciﬁc; P, probable.
TABLE 3. Risk factors for developing invasive fungal infection (IFI) after haematopoietic stem cell transplantation
Variables
IFI p-value
Hazard ratio
(95% CI)Yes No Univariate Multivariate
Sex (male/female) 22/17 154/98 0.601 – –
Age – – 0.393 – –
Disease status (standard risk/high risk) 24/15 210/42 0.004 0.001 2.916 (1.515–5.611)
Prior IFI history (yes/no) 4/35 19/233 0.527 – –
Prophylaxis with non-ﬂuconazole 4/35 27/225 0.931 – –
Number of mismatched HLA locui – – 0.477 – –
ANC engraftment >13 days 22/17 99/153 0.054 – –
PLT engraftment >17 days 29/10 130/122 0.009 0.027 2.432 (1.105–5.355)
Grade III–IV acute GVHD 10/29 33/219 0.052 0.019 2.407 (1.154–5.022)
Extensive chronic GVHD (n = 257) 11/21 51/174 0.293 – –
CMV reactivation 23/16 147/105 0.940 – –
Relapse 8/31 39/213 0.482 – –
CD4+ cells at day 30 (n = 186) – – 0.533 – –
CD4+ cells at day 60 (n = 162) – – 0.915 – –
CD4+ cells at day 90 (n = 176) – – 0.311 – –
CD4+ cells at day 180 (n = 110) – – 0.788 – –
CD4+ cells at day 365 (n = 79) – – 0.606 – –
Lymphocytes at day 30 (n = 283) – – 0.264 – –
Lymphocytes at day 60 (n = 267) – – 0.300 – –
Lymphocytes at day 90 (n = 250) – – 0.540 – –
Lymphocytes at day 180 (n = 203) – – 0.163 – –
Lymphocytes at day 365 (n = 141) – – 0.441 – –
ANC, absolute neutrophil count; CMV, cytomegalovirus; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; PLT, platelet.
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time of >13 days (p 0.054), platelet engraftment time of
>17 days (p 0.009) and grade III–IV acute GVHD (p 0.052)
were risk factors for IFI. Age, gender, cytomegalovirus reacti-
vation, the number of mismatched HLA loci, a prior history
of IFI, antifungal prophylaxis (ﬂuconazole vs. non-ﬂuconaz-
ole), relapse and peripheral blood lymphocyte/CD4+ cell
numbers at ﬁxed time points (days 30, 60, 90, 180, and 365)
were not statistically signiﬁcant. Factors with p <0.10 in the
univariate analysis were used for the multivariate analysis
with the Cox proportional hazards model. The variables
acute GVHD and chronic GVHD were also included in the
analysis. The results showed that platelet engraftment time
(p 0.027; hazard ratio (HR) 2.432; 95% CI 1.105–5.355), a
high risk of underlying disease status (p 0.001; HR 2.916;
95% CI 1.515–5.611) and grade III–IV acute GVHD (p 0.019;
HR 2.407; 95% CI 1.154–5.022) were risk factors for IFI. The
1-year cumulative incidence rates of IFI in patients with no,
one, two or three risk factors were 4.48%, 7.86%, 29.6% and
23.1%, respectively. Patients with two or three risk factors
had a signiﬁcantly higher incidence of IFI than those with no
or one risk factor (p <0.001) (Fig. 2b).
We further divided IFI into early IFI (£40 days) and late
IFI (>40 days) according to the time of occurrence. An analy-
sis of the risk factors for each group showed that a high risk
of underlying disease status (p 0.001; HR 4.157; 95% CI
1.844–9.370) was a risk factor for early IFI. Platelet engraft-
ment time (p 0.044; HR 3.975; 95% CI 1.038–15.230) and
extensive chronic GVHD (p 0.003; HR 5.051; 95% CI
1.756–14.531) were risk factors for late IFI.
Treatment and outcome of IFI
The initial antifungal drugs used for treatment in the 39 cases
of IFI were as follows: caspofungin for three cases, micafun-
gin for two cases, voriconazole for ﬁve cases, intravenous
itraconazole for 25 cases, and amphotericin B for four cases.
Only ten patients survived, and the survival rate was 25.6%
(Fig. 3a). Fot the 29 cases of mortality, the median time from
(a)
(b)
FIG. 2. (a) Cumulative incidence of invasive fungal infection (IFI)
after haploidentical haematopoietic stem cell transplantation without
in vitro T-cell depletion. (b) Cumulative incidence of IFI in patients
with 0–1 or 2–3 of the following factors: at high risk for underlying
disease, grade III–IV acute graft-versus-host disease, and platelet
engraftment time of >17 days.
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FIG. 3. (a) Probability of survival after diagnosis of invasive fungal
infection (IFI) in 39 recipients of haematopoietic stem cell transplants
from haploidentical donors. (b) The impact of IFI on overall survival.
Patients without IFI had signiﬁcantly better overall survival than
patients with IFI (p <0.001).
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diagnosis to death was 233 days (range: 0–1131 days). The
causes of mortality were as follows: 16 patients died of IFI,
seven of disease recurrence, and six from other causes. The
occurrence of IFI signiﬁcantly decreased overall survival. The
3-year survival rates for those with and without IFI were
24.4% and 71.2%, respectively (p <0.001) (Fig. 3b).
Discussion
Previous studies have suggested that patients undergoing
haploidentical HSCT with in vitro TCD have a higher inci-
dence of IFI than those undergoing matched sibling HSCT
[8], possibly because of the increased incidence of GVHD or
prolonged immunosuppression caused by in vitro TCD. How-
ever, no exact data related to the incidence of IFI after
haploidentical HSCT with in vitro TCD were available. The
Perugia group [9,10] and the Tubingen group [11] have
reported fungal-related mortality rates of 4.95% and 6%,
respectively. The above data, however, provided only the
incidence of lethal fungal infection, without reporting the
incidence of IFI.
In this study, the non-TCD method was adopted. To
our knowledge, this study presents the exact incidence of
IFI after haploidentical HSCT without in vitro TCD for the
ﬁrst time. The IFI-related mortality was 5.5% (16/291),
which is similar to that of TCD transplantation. The 1-year
cumulative incidence of IFI was 13.1%, which is similar to
that of transplantation from alternative donors. Some early
studies reported that the 1-year cumulative incidence of IFI
after allogeneic HSCT from matched sibling donors could
be up to 14–15% [12,13]; however, recent data have
shown that the incidence of IFI after transplantation from
matched siblings is signiﬁcantly lower than that after trans-
plantation from alternative donors [14]. It seems that the
incidence determined with this novel protocol was higher
than that of HSCT with HLA-matched siblings. However, a
direct comparison requires a prospective head-to-head
study. Our unpublished data suggest that immune reconsti-
tution after non-TCD haploidentical transplantation is
signiﬁcantly lower than that after HLA-matched transplanta-
tion in the ﬁrst 90 days (52nd American Society of Hema-
tology Annual Meeting, 2010, Abstract 2312). Most fungal
infections occurred within this period, suggesting that
poorer immune reconstitution may be responsible for the
high incidence. However, a proper comparison is lacking,
and this is an issue that needs to be addressed in future
investigations.
We found that grade III–IV acute GVHD and extensive
chronic GVHD were important risk factors for IFI after
haploidentical HSCT without in vitro TCD, which is consis-
tent with the ﬁndings of the HLA-matched transplant studies
mentioned above. In addition, our results show that the risk
of IFI in patients with delayed platelet engraftment (>17 days)
was 2.43 times higher than in those without delayed platelet
engraftment. The prognostic impact of delayed platelet
recovery on survival and infection has been studied previ-
ously [15,16]. Persistent thrombocytopenia after allogeneic
matched sibling peripheral blood stem cell transplantation
was found to be an independent predictor of opportunistic
infection and overall survival [17,18]. Our study showed that
delayed platelet recovery increased the risk of IFI. We
hypothesize that the impact of platelet recovery on IFI may
be attributable to the advanced disease status or the number
of infused CD34+ cells. These two factors were shown to be
the main ones affecting platelet recovery after haploidentical
HSCT without in vitro TCD in our previous study [19]. How-
ever, the exact role of delayed platelet recovery in IFI occur-
rence requires further investigation.
Although CD4+ Th1 cells have been shown to be protec-
tive against fungal infection in many studies [20,21], there
have been no studies focusing on total CD4 cell numbers. In
this study, the low lymphocyte/CD4+ counts were unable to
predict IFI at any of the time-points. It seems that the total
CD4+ cell number is not proportional to speciﬁc antifungal
immunity.
Some authors have considered patients with prior IFI to
be at high risk for IFI after transplantation, especially those
with a proven or probable IFI history [22]. In our study, a
history of IFI was not identiﬁed as a risk factor. The low
proportion (8/23) of proven or probable cases of prior IFI
may explain the difference between our study and the litera-
ture. Active prophylaxis with broad-spectrum antifungal
agents may also be the cause of this difference.
There are several issues in our study that cannot be
neglected. First, because G test detection has only recently
begun in our institute, only a minority of patients had G test
results during this period. Therefore, this study was based
on the early EORTC criteria. Because great differences exist
between the EORTC 2002 and EORTC 2008 criteria [23],
the results may also be different. This may be an important
limitation of this study. Second, the number of proven cases
was limited in this study, and possible IFI cases were consid-
ered to be non-fungal infections, which may have led to an
underestimation of the actual incidence.
In conclusion, IFI was an important complication after ha-
ploidentical HSCT without in vitro TCD. The prophylaxis
strategy should be optimized to reduce the IFI incidence,
especially for those at high risk. The therapeutic strategy
should also be improved to decrease IFI-related mortality.
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